ZYBERNO
Stock Report
Updated Aug 31, 2026

HERON THERAPEUTICS, INC. /DE/ (HRTX)

Healthcare • NASDAQ

$0.32

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
11.0/100
POOR BUSINESS
HERON THERAPEUTICS, INC. /DE/ (HRTX) scores 11/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-300.9%)
Debt-to-Equity (Solvency Risk):POOR (1.65x)
Operating Margin (Operational Efficiency):CRITICAL (-6.2%)
Return on Capital (Capital Efficiency):CRITICAL (-3.0%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

HERON THERAPEUTICS, INC. /DE/ (HRTX) stock report — Zyberno Score 11/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, HRTX generated -$20.86M in Owner Earnings. Capital was deployed as follows: $599.00K invested in capital expenditures. Reinvestment rate: 28.5%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.32
Market Cap:$60.53M

Valuation Multiples (3)

P/B Ratio:8.76x
P/S Ratio:0.40x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$45.51M

Price Action & Momentum (1)

% of 52-Week High:20.1%
B. Profitability Assessment

Return Metrics (5)

ROA:-13.6%
Reinvestment Rate:28.5%
Fundamental Growth Rate (g):-0.9%

Margin Analysis (3)

Operating Margin Ttm:-6.2%
Net Margin Ttm:-22.5%
Ebitda Margin:-4.7%

TTM Performance (3)

Gross Margin Ttm:70.1%
Operating Margin Ttm:-6.2%
Net Margin Ttm:-22.5%

Yield Metrics (2)

Earnings Yield:-$53.83
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-134.8%
Latest Earnings Filed:2026-08-10

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):8.9%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:2.49x
Quick Ratio:1.51x
Cash Ratio:0.22x

Leverage Analysis (3)

Debt To Equity Ttm:1.65x
Debt-to-Equity Ratio:1.65x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-0.26x
Times Interest Earned:-0.26

Capital Structure (4)

Working Capital:137,700,000.00
Cash And Cash Equivalents:20,721,000.00
Long Term Debt:$5.50M
Net Debt:-$15.02M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $151.18M
Linear Growth: 8.9%
📊 Click to view full HRTX Revenue analysis & methodology →
Cost Of Revenue Ttm:$45.24M

Profitability Breakdown (2)

Gross profit TTM: $105.94M
Linear Growth: 11.7%
📊 Click to view full HRTX Gross Profit analysis & methodology →
-$9.35M

Bottom Line Performance (3)

-$34.05M
Income Before Tax:$0.00
Ebitda Ttm:-7,055,000.00

Operating Expenses (5)

Operating Expenses:116,799,000.00
R And D Expense:12,303,000.00
Sga Expense:50,853,000.00
Income Tax Expense:$0.00
Interest Expense:9,605,000.00

Expense Ratios (3)

R And D To Revenue Percentage:32.7%
Sga To Revenue Percentage:135.0%
Ebitda Margin:-4.7%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$252.26M
Current Assets:$229.85M
Ppe Net:11,814,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:245,354,000.00
Current Liabilities:92,145,000.00
Long Term Debt:$5.50M
Short Term Debt:$200.00K

Equity & Capital (3)

Equity:$6.91M
Retained Earnings:-$1.95B
Common Stock:1,895,000.00

Working Capital Items (3)

Accounts Receivable:89,571,000.00
Inventory:90,585,000.00
Accounts Payable:11,641,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:3,178,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$20.26M-$20.86M

Investment Activities (2)

Investing Cash Flow:-$939.00K
Capital Expenditures Ttm:599,000.00

Financing Activities (3)

Financing Cash Flow:-$51.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:18,307,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:2,292,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.19
-$0.18
Earnings Per Share Ttm:-$0.18

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.79
Operating Cash Flow Per Share:-$0.14

Book Value & Capital (2)

Book Value Per Share:$0.04
Cash Per Share:0.11

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.60x
Working Capital Turnover Ttm:1.10x

Receivables Management (2)

Receivables Turnover Ttm:1.69x
Days Sales Outstanding Ttm:216.26

Inventory Management (2)

Inventory Turnover Ttm:0.50x
Days Inventory Outstanding Ttm:730.80

Payables & Cash Cycle (2)

Days Payable Outstanding:93.91
Cash Conversion Cycle:853.14
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:60.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$20.86M

Damodaran Growth Analysis (2)

Reinvestment Rate:28.5%
Fundamental Growth Rate (g):-0.9%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):8.9%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):11.7%
Book Value Growth Rate (Linear):-20.3%
C. Company Profile & Context

Corporate Information (6)

Symbol:HRTX
Company Name:HERON THERAPEUTICS, INC. /DE/
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:190.34M
Shares Outstanding Basic:190.34M
Shares Outstanding Diluted:190.34M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 21:53:28 UTC
Data Timestamp:2026-08-20T00:24:33.338358
Scroll to Top